After a quick FDA approval in a subset of endometrial cancer, GSK is back with more data for two Jemperli regimens in hopes of reaching a broader patient population. And AstraZeneca, utilizing a ...
GSK’s $2.2 billion agreement to acquire RAPT Therapeutics highlights a practical truth about immunology: some clinically ...
On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
GSK activity on the NYSE Composite highlights elevated options trading, institutional participation, and corporate updates ...
Ladies and gentlemen, a warm welcome to the GSK Full Year 2025 Results Call. I'm delighted to be joined today by Luke Miels, Nina Mojas, Deborah Waterhouse, Tony Wood and Julie Brown. And in our Q&A ...
GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results